Key terms
About MACK
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MACK news
Mar 27
5:13pm ET
Merrimack’s FDA Approval Milestone and Scheduled Dissolution Vote
Mar 27
4:31pm ET
Merrimack receives $225M milestone payment from Ipsen
Mar 07
4:52pm ET
Merrimack Pharmaceuticals Proposes Liquidation Plan
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Feb 13
4:34pm ET
Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval
Feb 13
4:19pm ET
Merrimack reports Ipsen announcement of FDA approval of Onivyde
No recent news articles are available for MACK
No recent press releases are available for MACK
MACK Financials
Key terms
Ad Feedback
MACK Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MACK Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range